Servier backs away from troubled cancer drug Pixuvri

28 February 2019

French independent drugmaker Servier has brought a cancer collaboration with US biotech firm CTI BioPharma (Nasdaq: CTIC) to a premature end, a filing to the US Securities and Exchange Commission reveals.

The firms had been working together on the non-Hodgkin's lymphoma treatment Pixuvri (pixantrone). The deal was originally signed in 2014, and was expanded in 2017.

Servier decided to sever links seven months after the therapy flopped in a key Phase III confirmatory trial in the EU. The confirmatory trial had been expected to deliver results by 2015, but did not read out until July 2018.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK